Focus On Asia
Sun launches tildrakizumab, its star psoriasis therapy in India seven years after US FDA approval at what’s seen as a carefully calibrated price point. Can it ruffle entrenched products like secukinumab?
In the head-to-head Phase III HARMONY trial in metformin-failed type 2 diabetes, HighTide's HTD1801 yielded a mean 1.12% reduction in HbA1c from baseline at 24 weeks, versus 0.93% for AstraZeneca’s Farxiga.
Akeso’s first-in-class PD-1/VEG-F bispecific ivonescimab is a landmark achievement for China’s biotech sector, but the firm is already expanding its ambitions in oncology and beyond, including a challenge to Roche in Alzheimer’s.
After AI’s magic wand status, it's now come to Google and Open AI CEOs talking of the likelihood of a bubble burst. In this interview, Parexel’s India head discusses how to view returns on such investments, the CRO’s own use cases and the US FDA’s keenness on transparency and open dialogue.
Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.
Biological E joins the ranks of Pfizer, GSK and Serum with WHO prequalification for its pneumococcal vaccine. As WHO's purchase data for Serum’s PSV10 indicate significant opportunity, Scrip spoke to Biological E on supply readiness and its application for exemption from price control in India
The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.
CRDMOs, CDMOs and GCCs are driving partnering and invigorating the wider ecosystem as India moves up the innovation value chain. CRDMOs are moving well beyond traditional outsourcing roles, a new report shows.
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Plus deals involving Adagene/Third Arc, Celltrion/TRiOar, Celltrion/Kaigene, ImmunoScape/Cue, Laekna/Qilu, Lilly/ABL, Lilly/Sanegene, Sanyou/ZJ Bio-Tech, TransThera/Neurocrine, Qyuns/Roche, Otsuka/4D Molecular, IASO/GC Cell, Chugai/Renalys, Henlius/Forlong and Teijin/Elevara.
Sichuan Biokin Pharmaceutical's BMS-partnered bispecific antibody-drug conjugate iza-bren had met both endpoints of PFS and OS in a China-only Phase III trial for the second-line treatment of esophageal squamous cell carcinoma.
Buoyed by the milestone AbbVie deal, Glenmark expects to “pay down” its debt and is also changing certain legacy practices as it seeks to ascend the value chain to become more of a branded company.
Setting its focus on oncology, immunology and rare diseases, the firm anticipates double-digit growth for 2030.
Korean biopharma firms are bracing for the impending US tariffs on pharmaceuticals and taking different approaches to tackle the situation.
Ascletis’ peptide co-formulation of ASC36 and ASC35 outperformed the co-formulation of Eli Lilly’s eloralintide and tirzepatide as well as eloralintide alone in a rat model, boosting the China-based firm’s confidence in upcoming clinical outcomes.
Zydus looks to fill up its coffers ahead of the next round of acquisitions, likely in the specialty drugs space, while US FDA approvals for generics to Lynparza and Vumerity and its first approvals in China and Canada point to a healthy pipeline
Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.
Scrip brings you its quarterly roundup of earnings and other key developments in the Korean pharma sector including the acquisition of Taxotere by Boryung and the progress of Hanmi’s obesity contender.
Lupin’s launch of liraglutide, a Victoza generic, in the US and tirzepatide development progresses its peptide plans. Meanwhile, pegfilgrastim – nearing US launch - is one of at least five biosimilars to be launched by 2030 amid regulatory easing
While Astellas and Daiichi Sankyo rang in double-digit growth, Eisai offset LOE impact with Leqembi’s performance. Takeda struggled with negative results but announced several growth initiatives.